In January 2019, Banner announced that the US Food and Drug Administration had granted tentative approval of Bafiertam, a monomethyl fumarate indicated for the treatment of patients with relapsing forms of multiple sclerosis, with full approval expected in 2020.
Approval may be accelerated based on the outcome of pending litigation with Biogen, Inc. regarding US Patent Number 7,619,001. Biogen's Tecfidera contains dimethyl fumarate rather than MMF.
Study BLS-11-109 is a randomized, double-blind study to compare gastrointestinal tolerability in healthy volunteers following five weeks of oral administration of Bafiertam or Tecfidera at their therapeutic doses.
Subjects will record daily GI symptoms. The primary endpoints include the rate and severity of gastrointestinal adverse events.
Relapsing-remitting multiple sclerosis, the most common form of MS, is a debilitating autoimmune disease characterized by inflammatory attacks to the central nervous system followed by periods of remission.
RRMS affects approximately 85% of patients diagnosed with MS, or an estimated 2 m people worldwide.
There is no cure for MS and disease progression and degree of impairment vary widely by patient depending on the location and extent of nerve damage.
Treatment regimens for RRMS focus on symptom management, slowing disease progression and reducing relapses.
Bafiertam (monomethyl fumarate) is indicated for the treatment of patients with relapsing forms of multiple sclerosis. While Bafiertam has been shown to activate the nuclear factor (erythroid-derived 2)-like 2 pathway, the precise mechanism of action has not been fully elucidated.
The prodrug of Bafiertam was shown in two separate studies to reduce the risk of relapse by 49% and 34%, and to reduce the number of relapses by 53% and 44%, compared to placebo.
Banner Life Sciences LLC, a privately held clinical-stage pharmaceutical company, combines a proven history of formulation expertise with proprietary technologies to create specialty pharmaceuticals that solve real unmet clinical needs.
GC Biopharma's GC1130A receives EMA Orphan Drug Designation
Guangzhou Fermion Technology's FZ008-145 IND application receives Chinese regulatory approval
Newron enrols 290 patients in schizophrenia study
Vistagen granted European patent for AV-101 to treat neuropathic pain
Alora Pharmaceuticals announces Relexxii commercial launch
IGC Pharma granted patent for Alzheimer's drug formulation
NRx Pharmaceuticals signs data agreement with Columbia University for IV Ketamine trials
Cambridge Cognition launches AQUA for automated quality assurance in CNS clinical trials
Shanghai Zhimeng Biopharma's CB03 receives US FDA orphan drug designation
Genentech's Alecensa demonstrates 76% reduction in disease recurrence risk
NRx Pharmaceuticals announces presentation at 8th Annual Dawson James Conference